C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 200—GeneralSubpart A—General Provisions

21 C.F.R. § 200.5 (2026)

Mailing of important information about drugs

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1982–2025 15citing cases
At a glance

Courts have cited this section in 15 opinions since 1982, 4 of them in the last five years.

Manufacturers and distributors of drugs and the Food and Drug Administration occasionally are required to mail important information about drugs to physicians and others responsible for patient care. In the public interest, such mail should be distinctive in appearance so that it will be promptly recognized and read. The Food and Drug Administration will make such mailings in accordance with the specifications set forth in this section. Manufacturers and distributors of drugs are asked to make such mailings as prescribed by this section and not to use the distinctive envelopes for ordinary mail.

(a) Use first class mail and No. 10 white envelopes.

(b) The name and address of the agency or the drug manufacturer or distributor is to appear in the upper left corner of the envelope.

(c) The following statements are to appear in the far left third of the envelope front, in the type and size indicated, centered in a rectangular space approximately 3 inches wide and 2 1/4 inches high with an approximately 3/8 inch-wide border in the color indicated:

(1) When the information concerns a significant hazard to health, the statement:

IMPORTANT DRUG WARNINGThe statement shall be in three lines, all capitals, and centered. “Important” shall be in 36 point Gothic Bold type. “Drug” and “Warning” shall be in 36 point Gothic Condensed type. The rectangle's border and the statement therein shall be red.

(2) When the information concerns important changes in drug package labeling, the statement:

IMPORTANT PRESCRIBING INFORMATIONThe statement shall be in three lines, all capitals, and centered. “Important” shall be in 36 point Gothic Bold type. “Prescribing” and “Information” shall be in 36 point Gothic Condensed type. The rectangle's border and the statement therein shall be blue.

(3) When the information concerns a correction of prescription drug advertising or labeling, the statement:

IMPORTANT CORRECTION OF DRUG INFORMATIONThe statement shall be in four lines, all capitals, and centered. “Important” shall be in 36 point Gothic Bold type. “Correction,” “Of Drug,” and “Information” shall be in 36 point Gothic Condensed type. The rectangle's border and the statement therein shall be brown.
The 15 cases that cite 21 C.F.R. § 200.5 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENPLIVA, Inc. v. Mensing, 564 U.S. 604 (2011).
cites § 200.5 1×cited by 420 cases
Where it cites § 200.5
“See Brief for Respondents 36; 21 CFR § 200.5 . Again, the FDA disagrees, and we defer to the agency’s views.”
2
GREENWeiss v. Fujisawa Pharm. Co., 464 F. Supp. 2d 666 (E.D. Ky. 2006).
cites § 200.5 2×cited by 8 cases
Where it cites § 200.5
“” 21 C.F.R. § 200.5 . “[Significant hazardfs] to health” are one example of the “important information” contemplated by this regulation.”
3
GREENOksenholt v. Lederle Labs., 656 P.2d 293 (Or. 1982).
cites § 200.5 1×cited by 47 cases
The case’s holding
Damages for intentional misrepresentation are limited to those that are a direct and necessary result of the defendant's acts or omissions.
Later courts cite it for
“damages properly recoverable in an action for intentional misrepresentation are those which are a direct and necessary result of defendant's acts or omissions.” · 5 citing courts
4
GREENPerry v. Novartis Pharma. Corp., 456 F. Supp. 2d 678 (E.D. Pa. 2006).
cites § 200.5 1×cited by 19 cases
Where it cites § 200.5
“, “Dear Doctor” letters containing such information) is not prohibited by these regulations.”
Later courts cite it for
“where, however, the fda has made a conclusive determination, positive or negative, as to the existence of a link between the drug at issue and some adverse health consequence, state law cannot mandate that a manufacturer include additional warning beyond those that the fda has determine to be appropriate to the risk.” · 2 citing courts
5
GREENDiana & Mark Sherman v. Pliva, Inc, 440 P.3d 1016 (Wash. Ct. App. 2019).
cites § 200.5 1×cited by 7 cases
Where it cites § 200.5
“2d 580 (2011); 21 C.F.R. 200.5. 4 Sherman initially argues that we should hold that the commissioner erred in granting discretionary review under RAP 2.”
Later courts cite it for
“a drug manufacturer's duty to warn is limited to providing a package insert that accompanies the product,” · 2 citing courts
6
YELLOWGaeta v. Perrigo Pharm. Co., 630 F.3d 1225 (9th Cir. 2011).
cites § 200.5 1×cited by 15 cases
Vacated (GVR) by L. Perrigo Co. v. Gaeta (2011): the Supreme Court's order in this case remanded it for further consideration; read the decision on remand before relying on it.
Where it cites § 200.5
“See 21 C.F.R. § 200.5 . When the FDA first adopted its labeling regulations, well before the Hatch-Wax-man Amendments, it made clear that the labeling requirements “do not prohibit a manufacturer .”
7
GREENTeva Pharm. USA, Inc. v. Superior Court, 217 Cal. App. 4th 96 (Ct. App. 2013).
cites § 200.5 1×cited by 14 cases
Where it cites § 200.5
“( 21 C.F.R. § 200.5 (2013).) These mailings are commonly referred to as “Dear Doctor” letters.”
8
GREENChristopher v. Cutter Labs., 53 F.3d 1184 (11th Cir. 1995).
cites § 200.5 1×cited by 27 cases
Where it cites § 200.5
“21 C.F.R. § 200.5 (1983). . Whole blood is obtained from a direct blood donation and is used rarely because of the small amount of clotting Factor VIII and the potential for fatal vascular overload and congestive heart failure.”
Later courts cite it for
“the learned intermediary rule provides that the failure of the manufacturer to provide the physician with an adequate warning of the risks associated with a prescription product is not the proximate cause of a patient's injury if the prescribing physician had independent knowledge of the risk that the adequate warning should have communicated.” · 8 citing courts
9
GREENWalls v. Armour Pharm. Co., 832 F. Supp. 1467 (M.D. Fla. 1993).
cites § 200.5 1×cited by 5 cases
Where it cites § 200.5
“21 C.F.R. § 200.5 (1982). This regulation further specified the type of envelope and print size for the FDA to use in such mailings.”
10
GREENPLIVA, Inc. v. Mensing, 564 U.S. 604 (2011).
cites § 200.5 2×cited by 0 cases
Where it cites § 200.5
“See Brief for Respondents 36; 21 CFR §200.5 . Again, the FDA disagrees, and we defer to the agency’s views.”
The case’s holding
Federal law preempts state law failure-to-warn claims against generic drug manufacturers when federal regulations require generic labels to be identical to those of brand-name drugs.
Later courts cite it for
“where state and federal law 'directly conflict,' state law must give way.” · 48 citing courts
11
NO FLAGCamejo v. Angelini Pharma Inc., No. N19C-09-023 (Del. Super. Ct. Jan. 15, 2021).
cites § 200.5 1×cited by 0 cases
Where it cites § 200.5
“Camejo’s attempt to devise a California state-law claim for failure to warn derived from his suggested duty to send a “Dear Doctor” letter highlighting the priapism warning fails both on the law and on logic.”
12
GREENCtr. for Env't Health v. Perrigo Co., 89 Cal. App. 5th 1 (Ct. App. 2023).
cites § 200.5 1×cited by 0 cases
Where it cites § 200.5
“4th 96, 104 ; see 21 C.F.R. § 200.5 .) 22 Two years later, Bartlett applied Mensing to hold that “state-law design-defect claims that turn on the adequacy of a drug’s warnings are pre- empted by federal law.”
13
NO FLAGChristine Jankowski v. Zydus Pharm. USA Inc, No. 22-2212 (3d Cir. July 24, 2023).
cites § 200.5 1×cited by 0 casesunpublished
Where it cites § 200.5
“” 21 C.F.R. § 200.5 . 4 Plaintiffs also alleged that Zydus had a duty to correct allegedly inaccurate information about Amiodarone in the third-party physician reference sources.”
14
GREENExela Pharma Sciences, LLC v. Sandoz, Inc., 486 F. Supp. 3d 1001 (W.D.N.C. 2020).
cites § 200.5 1×cited by 0 casesunknown
Where it cites § 200.5
“See 21 C.F.R. § 200.5 . The FDA can mandate and oversee the distribution of Dear Healthcare Provider letters in conjunction with its oversight of drug shortages.”
15
NO FLAGNexus Pharm., LLC v. Long Grove Pharm., LLC, No. 1:24-cv-10444 (D. Mass. Jan. 13, 2025).
cites § 200.5 1×cited by 0 casesunknown
Where it cites § 200.5
“1 at ¶¶ 8, 40]; 21 C.F.R. § 200.5 ; FDA, Guidance for Industry: Dear Health Care Provider Letters: Improving Communication of Important Safety Information, at 1 (2014).”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198220032025

One bar per year. Tallest: 3 cases in 2011. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Cal. Ct. App.2SCOTUS211th Cir.13rd Cir.19th Cir.1Del. Super. Ct.1M.D. Fla.1E.D. Ky.1

The 8 courts with the most citing cases, of 13 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com